The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies

JD Campbell; R Perry; NG Papadopoulos; J Krishnan; Guy Brusselle; A Chisholm; L Bjermer; M Thomas; E van Ganse; M Berge; J Quint; D Price; N Roche

doi:10.1186/s13601-019-0256-9

The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies

JD Campbell, R Perry, NG Papadopoulos, J Krishnan, Guy Brusselle, A Chisholm, L Bjermer, M Thomas, E van Ganse, M Berge, J Quint, D Price, N Roche

Epidemiology

Research output: Contribution to journal › Article › Academic › peer-review

10 Citations (Scopus)

1 Downloads (Pure)

Original language	Undefined/Unknown
Article number	21
Journal	Clinical and Translational Allergy
Volume	9
DOIs	https://doi.org/10.1186/s13601-019-0256-9
Publication status	Published - 2019

Access to Document

10.1186/s13601-019-0256-9

Repub_116206_O-A.pdfFinal published version, 880 KB

http://hdl.handle.net/1765/116206

Cite this

Campbell, JD., Perry, R., Papadopoulos, NG., Krishnan, J., Brusselle, G., Chisholm, A., Bjermer, L., Thomas, M., van Ganse, E., Berge, M., Quint, J., Price, D., & Roche, N. (2019). The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies. Clinical and Translational Allergy, 9, [21]. https://doi.org/10.1186/s13601-019-0256-9

Campbell, JD ; Perry, R ; Papadopoulos, NG ; Krishnan, J ; Brusselle, Guy ; Chisholm, A ; Bjermer, L ; Thomas, M ; van Ganse, E ; Berge, M ; Quint, J ; Price, D ; Roche, N. / The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies. In: Clinical and Translational Allergy. 2019 ; Vol. 9.

@article{a1ea222cbb74494d90247e34a73fc3aa,

title = "The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies",

author = "JD Campbell and R Perry and NG Papadopoulos and J Krishnan and Guy Brusselle and A Chisholm and L Bjermer and M Thomas and {van Ganse}, E and M Berge and J Quint and D Price and N Roche",

year = "2019",

doi = "10.1186/s13601-019-0256-9",

language = "Undefined/Unknown",

volume = "9",

journal = "Clinical and Translational Allergy",

issn = "2045-7022",

publisher = "BioMed Central Ltd.",

}

Campbell, JD, Perry, R, Papadopoulos, NG, Krishnan, J, Brusselle, G, Chisholm, A, Bjermer, L, Thomas, M, van Ganse, E, Berge, M, Quint, J, Price, D & Roche, N 2019, 'The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies', Clinical and Translational Allergy, vol. 9, 21. https://doi.org/10.1186/s13601-019-0256-9

The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies. / Campbell, JD; Perry, R; Papadopoulos, NG; Krishnan, J; Brusselle, Guy; Chisholm, A; Bjermer, L; Thomas, M; van Ganse, E; Berge, M; Quint, J; Price, D; Roche, N.

In: Clinical and Translational Allergy, Vol. 9, 21, 2019.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies

AU - Campbell, JD

AU - Perry, R

AU - Papadopoulos, NG

AU - Krishnan, J

AU - Brusselle, Guy

AU - Chisholm, A

AU - Bjermer, L

AU - Thomas, M

AU - van Ganse, E

AU - Berge, M

AU - Quint, J

AU - Price, D

AU - Roche, N

PY - 2019

Y1 - 2019

U2 - 10.1186/s13601-019-0256-9

DO - 10.1186/s13601-019-0256-9

M3 - Article

VL - 9

JO - Clinical and Translational Allergy

JF - Clinical and Translational Allergy

SN - 2045-7022

M1 - 21

ER -